1195-81-9

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 1-HYDROXYMETHYLCYCLOBUTANECARBOXYLATE is used as a synthetic intermediate for the development of pharmaceuticals. Its cyclobutane ring and hydroxymethyl group provide a structural foundation that can be further modified to create new drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 1-HYDROXYMETHYLCYCLOBUTANECARBOXYLATE serves as a key component in the synthesis of agrochemicals. Its unique chemical properties enable the creation of compounds that can be used in pest control and crop protection, contributing to enhanced agricultural productivity.
Used in Flavor and Fragrance Industry:
ETHYL 1-HYDROXYMETHYLCYCLOBUTANECARBOXYLATE is utilized as a precursor in the production of flavor and fragrance compounds. Its ability to form esters makes it a valuable contributor to the creation of scents and tastes in various consumer products, including food, beverages, and cosmetics.
ETHYL 1-HYDROXYMETHYLCYCLOBUTANECARBOXYLATE is typically handled and stored under controlled conditions to ensure safety and prevent any potential hazards associated with its use, reflecting the importance of proper management in chemical applications.

Upstream product

• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 50-00-0 formaldehyd 
• 14924-53-9 ethyl cyclobutylcarboxylate 

Downstream Products

• 1192181-61-5 (1-ethenylcyclobutyl)diphenylmethanol 
• 1192181-78-4 ethyl 4-(2-cyclobutylidenethyl)benzoate 
• 1383001-19-1 ethyl 1-{[(5-bromo-4-methylpyridin-2-yl)oxy]methyl}cyclobutanecarboxylate 
• 1383001-40-8 1-{[(5-{3-chloro-4-[5-(trifluoromethyl)-1H-imidazol-2-yl]phenyl}-4-methylpyridin-2-yl)oxy]methyl}cyclobutanecarboxylic acid 
• 1383001-39-5 1-{[(5-{3-chloro-4-[4-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl]phenyl}-4-methylpyridin-2-yl)oxy]methyl}cyclobutanecarboxylic acid 
• 1383001-38-4 ethyl 1-{[(5-{3-chloro-4-[4-(trifluoromethyl)-1-{[2-(trimethyl-silyl)ethoxy]methyl}-1H-imidazol-2-yl]phenyl}-4-methylpyridin-2-yl)oxy]methyl}-cyclobutanecarboxylate 
• 1383001-26-0 1-{[(5-{3-fluoro-4-[5-(trifluoromethyl)-1H-imidazol-2-yl]phenyl}-4-methylpyridin-2-yl)oxy]methyl}cyclobutanecarboxylic acid 
• 1383001-25-9 1-{[(5-{3-fluoro-4-[4-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl]phenyl}-4-methylpyridin-2-yl)oxy]methyl}cyclobutanecarboxylic acid 
• 1383001-24-8 ethyl 1-{[(5-{3-fluoro-4-[4-(trifluoro-methyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl]phenyl}-4-methyl-pyridin-2-yl)oxy]methyl}cyclobutanecarboxylate 
• 1383001-20-4 ethyl 1-({[4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]oxy}methyl)cyclo-butanecarboxylate 
• 57742-93-5 ethyl 1-formylcyclobutanecarboxylate 
• 114671-88-4 C₁₅H₂₀O₃ 
• 1610455-66-7 C₁₃H₁₅ClO₂ 
• 1387563-26-9 C₁₃H₁₆O₃ 

Relevant academic research and scientific papers

Palladium(II)-catalyzed enantioselective C(sp3)-H activation using a chiral hydroxamic acid ligand

An enantioselective method for Pd(II)-catalyzed cross-coupling of methylene β-C(sp3)-H bonds in cyclobutanecarboxylic acid derivatives with arylboron reagents is described. High yields and enantioselectivities were achieved through the development of chiral mono-N-protected α-amino-O- methylhydroxamic acid (MPAHA) ligands, which form a chiral complex with the Pd(II) center. This reaction provides an alternative approach to the enantioselective synthesis of cyclobutanecarboxylates containing α-chiral quaternary stereocenters. This new class of chiral catalysts also show promises for enantioselective β-C(sp3)-H activation of acyclic amides.

Compounds Which Selectively Modulate The CB2 Receptor

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu

Synthesis of (2-arylethylidene)cyclobutanes by palladium-catalyzed reactions of aryl halides with homoallyl alcohols bearing a trimethylene group at the allylic position

Treatment of aryl bromides with homoallyl alcohols bearing a trimethylene group at the allylic position in the presence of cesium carbonate under palladium catalysis affords (2-arylethylidene) cyclobutanes selectively. The selective formation of the alkylidenecyclobutane skeleton results from regiospecific retroallylation of the homoallyl alcohols, which accompanies the transposition of the double bonds. Georg Thieme Verlag Stuttgart.

Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

The synthesis and SAR of a series of arylsulfonylpiperazine inhibitors of 11β-HSD1 are described. Optimization rapidly led to potent, selective, and orally bioavailable inhibitors demonstrating efficacy in a cynomolgus monkey ex vivo enzyme inhibition model.

Spiro derivatives as lipoxygenase inhibitors

The present invention is concerned with certain novel spiro substituted heterocylic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful

ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO

The present invention provides Aryl Sulfonamide Compounds having the formula: (I); and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.